Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study
Open Access
- 30 April 2026
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (5) , e70563
Abstract
Using a real‐world psoriasis cohort, we established the pharmacokinetic‐pharmacodynamic (PKPD) relationship for the biologic therapy adalimumab and evaluated the clinical utility and cost‐effectiveness of a proactive therapeutic drug monitoring (TDM) strategy. A total of 543 patients on adalimumab monotherapy for psoriasis provided 946 pharmacokinetic samples and 1700 Psoriasis Area Severity Index (PASI) disease severity measurements. To describe the PASI change over time, a one‐compartment linear PK model with first‐order absorption and elimination was linked to a turnover mechanism of skin lesions. Based on the PKPD relationship and a predefined therapeutic range, real‐time stochastic simulation was performed for a proactive TDM strategy, where trough levels guided dose escalation or reduction. Compared to the standard care, the TDM strategy improved PASI90 and PASI75 by 37.5% and 12.8%, respectively, with a 25.9% increase in drug costs. In the future, incorporating the PKPD model into a Bayesian therapeutic monitoring algorithm could facilitate individualized adalimumab dosing.Keywords
This publication has 43 references indexed in Scilit:
- The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysisAnnals of the Rheumatic Diseases, 2013
- Immunogenicity to Therapeutic Proteins: Impact on PK/PD and EfficacyThe AAPS Journal, 2012
- A Fast Method for Testing Covariates in Population PK/PD ModelsThe AAPS Journal, 2011
- Assessing Response and Loss of Response to Biological Therapies in IBDAmerican Journal of Gastroenterology, 2011
- A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patientsJournal of Immunological Methods, 2010
- Population‐Based Exposure‐Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque PsoriasisThe Journal of Clinical Pharmacology, 2010
- Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL‐12/23p40, in Patients With Moderate to Severe Plaque PsoriasisThe Journal of Clinical Pharmacology, 2009
- Extensions to the Visual Predictive Check to facilitate model performance evaluationJournal of Pharmacokinetics and Pharmacodynamics, 2008
- Psoriasis assessment tools in clinical trialsAnnals of the Rheumatic Diseases, 2005
- Simultaneous vs. Sequential Analysis for Population PK/PD Data I: Best-Case PerformanceJournal of Pharmacokinetics and Pharmacodynamics, 2003